El interés en corto de Intellia Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Intellia Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Informe de interés en corto

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

The electric vehicle market lost some juice earlier in 2024, but October showed a sector comeback with some serious battery power.
According to Cox Automotive, new EV sales were up 2.3% for the month and have cleared one million units for the year to date. Cox attributed the growth to aggressive dealer incentives and attractive vehicle leasing deals.
But that growth has yet to translate into success for sector portfolio players. A case in point is the benchmark Global X Autonomous &amp; Electric Vehicles ETF (DRIV), which is losing ground, down -6.61% for the year.
That's the trouble with EV stocks and funds, market mavens say. While the long-term glide path looks clear enough for electric vehicles, mile marker to mile marker, the sector isn't gaining much steam.
Here&#8217;s why those troubles may continue in 2025 &#8211; with one huge potential exception.
&#8220;There is a lot of opportunity in the EV market, but it still faces significant challenges, mainly geared around consumer confusion," says David Boice, CEO of Team Velocity, an automotive technologies firm in Washington, D.C. &nbsp;"The upsides are that EVs are changing how the government can incentivize vehicles, allowing OEMs to explore new tech, and cities are constantly expanding infrastructure for mass adoption and sustainability."
The downsides, unfortunately, are stacking up right now.
"A lack of resources leaves consumers uncertain; tax credits, charging time, and long-term savings are all things Americans need to understand before buying an EV," Boice says. "OEMs and dealers need to be providing clear messaging about their vehicles to make sure there is as little friction surrounding the EV purchasing process as possible.&#8221;
Another issue vexing potential investors is how the Trump administration's EV policies will play out.
"The biggest downsides right now have to do with affordability," says  KC Boyce, vice president at Escalent, a global market research and data advisory firm. "If the EV purchase tax credit goes away under Trump 2.0 and automakers don't continue a relentless pursuit of affordable models, EV adoption will run out of juice."
<a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">[Two-Week Free Access to Pro-Level Trading Tools]</a>
What the Experts Are Saying About EV Stocks
With that framework in mind, where are EV stocks headed in what promises to be a tumultuous 2025? Here's a snapshot of what sector plays stand out and why.
Tesla (TSLA). Elon Musk's favorite car company has seen its share price rise by 34% so far in 2024, comfortably ahead of the S&amp;P 500 Index, which is up 26% for the year.
When it comes to investing, companies that show they're in it for the long haul are almost always a good bet, and Tesla follows that script to the letter.
"Tesla is an obvious choice as an EV favorite — they've practically defined the electric vehicles category," says Mark Whitley, founder and CEO at Whits Corporation, a sustainable technology firm in St. Louis, Mo.
Investors shouldn't pay too much attention to the highly vocal Musk, but the Trump administration's aggressive stance on tariffs and EV credits is another story.&nbsp; "Despite Elon Musk saying he wants Trump to kill EV tax credits, Tesla benefits greatly from the current regulatory regime," Boyce says.
Chargeback (CHPT). This Campbell, Cal.-based electric vehicle charging network provider went public last March via a special purchase acquisition company (SPAC) deal and has plummeted over 90% since the rollout.
Yet the company operates 315,000 charging ports in the US and abroad, giving it a big advantage in a burgeoning industry. It also has over one million roaming charging points, which represents a robust number in another growing EV sector.
The company's broad-based operational stance should eventually stabilize the stock price, but it also has other advantages.
"Let's not forget the infrastructure part," Whitley says. "Companies like ChargePoint, which focuses on electric vehicle charging solutions, are a way to invest in the sector without betting on any specific vehicle."
BHP Group, LTD (BHP). This nickel mining company is a good supply/demand stock right now, as nickel is one EV-linked commodity company that can take advantage of rising EV battery needs.
The stock is down 24% for the year, but with production pressures pushing nickel demand up, BHP may make sense for sector investors over the long haul.
"There's potential in businesses that develop EV infrastructure, like battery technology and charging networks," says Dre Villeroy, CEO at Beyorch, a private equity firm in Los Angeles, Cal. "They are essential to expanding the sector."
Going Forward
Ultimately, investors' short-term sector issues against long-term potential will matter most, and lead them to choose sector stocks accordingly.
"I suspect EV sales will be very strong in December due to the prospect of the tax credit going away and may slow down for a bit as the ultimate resolution of the tax credit is under discussion in Washington," Boyce says. "Over time, however, EVs will continue a growth trajectory."
"Just how quick a growth trajectory really depends on where we land with the regulatory and tax environment in Washington," he adds.
Step up your trading with Benzinga Pro's advanced news alerts, scanners, and real-time market insights. Join over 6,000 traders who rely on these tools to spot opportunities first. <a href="https://www.benzinga.com/pro/checkout/benzinga-pro-essential-2024/?t=be16bespmirebz36&amp;utm_source=WebRD-1219">Start your free trial and trade smarter today.</a>
Image via Shutterstock

Opinion

Trading Ideas

Where EV Stocks Are Going In 2025

QBTS

QMCO

QUBT

RGTI

Shares of quantum computing companies are trading lower. The industry may be pulling back following recent strength.

Macro Economic Events

Market Summary

Economics

General

Benzinga Market Summary: S&P Rises Following GDP And Jobless Claims Data

Nike Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) will be reporting its second-quarter earnings on Thursday. Wall Street expects 64 cents in EPS and $12.13 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=NKE" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is down 37.30% over the past year, 19.54% over the past six months. 
<h1 class="wp-block-heading">Nike Facing Slowing Growth, Stock Slipping</h1>
Nike has faced consistent challenges in recent quarters, with growth slowing and stock performance reflecting the headwinds. 
Shares have gapped down after earnings in four consecutive reports, including October, when the company missed revenue expectations and withdrew its full-year guidance. 
Weakness in North America and China, coupled with a 15% drop in digital sales and a 13% decline in direct-to-consumer sales, has weighed heavily on results. Nike's strategic pivot to prioritize direct sales over wholesale channels like Foot Locker Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) and DSW has yet to deliver the desired rebound, leaving investors cautious ahead of its upcoming earnings release.
Let&#8217;s look at what the charts indicate for Nike stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42562515/nike-q2-earnings-preview-analyst-says-athletic-brand-early-in-turnaround-journey-with-new-ceo">Nike Q2 Earnings Preview: Analyst Says Athletic Brand Early In &#8216;Turnaround Journey&#8217; With New CEO</a>
<h1 class="wp-block-heading">Nike Stock Chart Bearish Ahead Of Q2 Earnings&nbsp;</h1>
Nike&#8217;s technical indicators paint a bearish picture ahead of its earnings release. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19064511/Screenshot-2024-12-19-at-4.40.59-PM.png" alt="" class="wp-image-699488" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19064511/Screenshot-2024-12-19-at-4.40.59-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/19064511/Screenshot-2024-12-19-at-4.40.59-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121924&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
The stock is trading below its eight-day, 20-day and 50-day exponential moving averages, signaling strong bearish momentum and sustained selling pressure. With Nike stock at $76.90, below the eight-day simple moving average (SMA) of $77.57, 20-day SMA of $77.69, 50-day SMA of $78.35 and 200-day SMA of $84.77, the trend points to potential for further downside.
The moving average convergence/divergence (MACD) indicator at a negative 0.12 confirms a bearish signal, while the relative strength index (RSI) at 46.09 suggests the stock is approaching oversold territory but remains neutral for now.
<h1 class="wp-block-heading">Nike Analysts See 17% Upside</h1>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/NKE/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Nike stock stands at an Outperform currently with a price target of $94.10. The latest analyst ratings from Wells Fargo, Evercore ISI Group and Deutsche Bank suggest an average price target of $90.33 for Nike stock, implying a 17% upside potential.
NKE Price Action: Nike stock is down 0.065% at $76.85 at publication on Thursday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42569953/dow-dips-over-1100-points-falling-for-10th-session-as-powell-adopts-hawkish-stance-greed-index-moves-to-fear-zone">Dow Dips Over 1,100 Points, Falling For 10th Session As Powell Adopts Hawkish Stance: Greed Index Moves To &#8216;Fear&#8217; Zone</a></li>
</ul>
Photo: Pixfly on Shutterstock

Technicals

Previews

Nike's Earnings Loom With Bearish Signals: Will The Swoosh Bounce Back?

WIIM

Psyence Biomedical shares are trading higher. The company announced it has entered into an IP licensing and mutual exclusivity agreement with Optimi Health Corp.

Barrington Research analyst Gary Prestopino maintains Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) with a Outperform and raises the price target from $360 to $410.

News

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Kadant, Raises Price Target to $410

On Thursday, Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) revealed topline results from two pivotal Phase 3 trials of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42572326/merck-announces-topline-results-from-pivotal-phase-3-trials-evaluating-investigational-once-daily-" rel="noreferrer noopener">with HIV-1 infection</a>.
The trials included patients who were virologically suppressed on different antiretroviral therapy regimens, including antiretroviral therapy regimens [baseline antiretroviral therapy (<a target="_blank" href="https://clinicaltrials.gov/study/NCT05631093" rel="noreferrer noopener">bART</a>) and Bictegravir/​Emtricitabine/​Tenofovir Alafenamide (<a target="_blank" href="https://clinicaltrials.gov/study/NCT05630755" rel="noreferrer noopener">BIC/​FTC/​TAF</a>).
DOR/ISL was demonstrated to be non-inferior to bART in open-label trial MK-8591A-051 and non-inferior to BIC/FTC/TAF in double-blind trial MK-8591A-052.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41434127/gilead-sciencesmercks-investigational-once-weekly-hiv-combo-therapy-shows-sustained-virus-suppres" rel="noreferrer noopener">Gilead Sciences/Merck&#8217;s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks</a>
Trial MK-8591A-052 did not meet the superiority criteria, but both trials also met the primary safety objectives.
The company plans to present detailed findings from these trials at a future scientific congress and file the data with regulatory authorities.
In the U.S., doravirine is approved for the treatment of adults with HIV-1 in combination with other antiretrovirals, as a single agent (PIFELTRO) and a component of a single-tablet regimen [DELSTRIGO; doravirine, lamivudine, and tenofovir disoproxil fumarate (DOR/3TC/TDF)].
Islatravir (MK-8591), Merck&#8217;s investigational drug, is being evaluated in multiple early and late-stage clinical trials in combination with other antiretroviral therapies for the treatment of HIV-1.
In addition to the MK-8591A-051 and MK-8591A-052 trials, ongoing Phase 3 trials of DOR/ISL include&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT05705349&amp;esheet=54169231&amp;newsitemid=20241219661570&amp;lan=en-US&amp;anchor=MK-8591A-053&amp;index=3&amp;md5=289fad4b8e112f0df5a7c56584cbba83" rel="noreferrer noopener">MK-8591A-053</a> in people with HIV who had not previously received treatment (treatment-naïve) and&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT05766501%3Fterm%3Dislatravir%26page%3D2%26rank%3D12&amp;esheet=54169231&amp;newsitemid=20241219661570&amp;lan=en-US&amp;anchor=MK-8591A-054&amp;index=4&amp;md5=93a25503967ab506b3a49091d73d2bc9" rel="noreferrer noopener">MK-8591A-054</a> evaluating open-label DOR/ISL in individuals who participated in earlier Phase 3 trials of DOR/ISL.
Price Action: MRK stock is up 1.18% at $99.50 at last check Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42598735/nip-group-to-see-14-revenue-growth-in-2025-analyst-projects-solid-long-term-growth" target="_blank" rel="noreferrer noopener">From Anime To Abu Dhabi: Analyst Sees NIP Group Transforming Entertainment And Tech</a></li>
</ul>
Photo: HIV/AIDS ribbon via Shutterstock.

Biotech

Equities

Large Cap

Health Care

Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials

According to a report, U.S. healthcare spending grew by 7.5% to $4.9 trillion in 2023. The increase was fueled by higher enrollment in private health plans and expanded use of medical services, driven by legislative changes and post-pandemic rebounds in care utilization.
Healthcare spending accounted for 17.6% of the U.S. economy, outpacing GDP growth of 2.9%. Spending on retail prescription drugs <a target="_blank" href="https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2024.01375" rel="noreferrer noopener">saw</a> the most significant rise, jumping 11.4% to $449.7 billion.
The report attributed this to increased use of medications for obesity and diabetes.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41866438/donald-trumps-second-term-could-reshape-us-healthcare-system-with-major-impacts-on-affordable-care-act-and-medicare" rel="noreferrer noopener">Donald Trump&#8217;s Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare</a>
The rapid growth in spending for drugs used to treat diabetes and obesity contributed to faster overall growth in retail prescription drug expenditures and private health insurance and Medicare spending growth.
Hospital care spending rose 10.4% to $1.5 trillion in 2023, marking the fastest growth since 1990. Hospital discharges increased by 1.6%, with Medicare beneficiaries driving higher outpatient service utilization.
Spending on physician and clinical services also climbed by 7.4% to $978 billion, with private insurance and Medicare patients contributing to this rise.
Enrollment in private health insurance grew by 1.6%, adding 3.3 million Americans.
Private insurance spending surged by 11.5%, reaching $1.5 trillion and accounting for 30% of national healthcare expenditures.
Medicare spending grew 8.1% to $1 trillion, representing 21% of total healthcare spending. Medicaid spending, however, grew more slowly at 7.9%, reflecting the end of the COVID-19 public health emergency.
The report also revealed that 92.5% of Americans had health insurance in 2023, up from 92.0% in 2022, underscoring the broader coverage expansion in recent years.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/24/12/42599673/amazon-has-20000-rivian-electric-delivery-vans-in-fleet-heres-what-could-be-next-for-both-companies">Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here&#8217;s What Could Be Next For Both Companies</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Government

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Pharmaceuticals Index Fund

iShares Dow Jones US Health Care Provides Index Fund

iShares Trust Dow Jones US Healthcare Sector Index Fund

Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services

Whales with a lot of money to spend have taken a noticeably bearish stance on Upstart Hldgs.
Looking at options history for Upstart Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) we detected 56 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 42% with bearish.
From the overall spotted trades, 11 are puts, for a total amount of $386,250 and 45, calls, for a total amount of $4,604,770.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $125.0 for Upstart Hldgs during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Upstart Hldgs stands at 1568.8, with a total volume reaching 16,406.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Upstart Hldgs, situated within the strike price corridor from $20.0 to $125.0, throughout the last 30 days.
<h3>Upstart Hldgs Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734633111_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$14.2</td>
<td>$13.75</td>
<td>$13.75</td>
<td>$80.00</td>
<td>$490.8K</td>
<td>3.2K</td>
<td align="right">417</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$31.15</td>
<td>$28.45</td>
<td>$30.0</td>
<td>$80.00</td>
<td>$300.0K</td>
<td>397</td>
<td align="right">203</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.2</td>
<td>$14.8</td>
<td>$14.8</td>
<td>$125.00</td>
<td>$296.0K</td>
<td>225</td>
<td align="right">208</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$23.0</td>
<td>$22.9</td>
<td>$23.0</td>
<td>$80.00</td>
<td>$287.5K</td>
<td>471</td>
<td align="right">125</td>
</tr>
<tr>
<td>UPST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$55.6</td>
<td>$53.0</td>
<td>$53.6</td>
<td>$20.00</td>
<td>$214.4K</td>
<td>4.0K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>

<h3>About Upstart Hldgs</h3>
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. Upstart's platform includes personal loans, automotive retail and refinance loans, home equity lines of credit and small dollar loans.
Having examined the options trading patterns of Upstart Hldgs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Upstart Hldgs's Current Market Status</h3>
<ul>
<li>With a volume of 5,260,367, the price of UPST is up 2.78% at $75.36. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 54 days.</li>
</ul>
<h3>Expert Opinions on Upstart Hldgs</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $84.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Needham has upgraded their rating to Buy and adjusted the price target to $100. 
&#x2A; Showing optimism, an analyst from Redburn Atlantic upgrades its rating to Buy with a revised price target of $95. 
&#x2A; An analyst from JP Morgan downgraded its action to Underweight with a price target of $57. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Upstart Hldgs with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

UPST

This Is What Whales Are Betting On Upstart Hldgs

Financial giants have made a conspicuous bullish move on Baidu. Our analysis of options history for Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) revealed 9 unusual trades.
Delving into the details, we found 77% of traders were bullish, while 22% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $95,392, and 6 were calls, valued at $270,833.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $50.0 to $100.0 for Baidu over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of Baidu stands at 2282.0, with a total volume reaching 2,455.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Baidu, situated within the strike price corridor from $50.0 to $100.0, throughout the last 30 days.
<h3>Baidu Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734633105_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$17.2</td>
<td>$16.5</td>
<td>$16.92</td>
<td>$70.00</td>
<td>$84.6K</td>
<td>1.1K</td>
<td align="right">51</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$22.25</td>
<td>$21.55</td>
<td>$21.55</td>
<td>$90.00</td>
<td>$53.8K</td>
<td>565</td>
<td align="right">53</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$45.5</td>
<td>$42.5</td>
<td>$44.56</td>
<td>$50.00</td>
<td>$44.5K</td>
<td>67</td>
<td align="right">10</td>
</tr>
<tr>
<td>BIDU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.4</td>
<td>$14.1</td>
<td>$14.2</td>
<td>$100.00</td>
<td>$42.6K</td>
<td>2.1K</td>
<td align="right">56</td>
</tr>
<tr>
<td>BIDU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$22.5</td>
<td>$21.6</td>
<td>$22.14</td>
<td>$90.00</td>
<td>$33.2K</td>
<td>565</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Baidu</h3>
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 72% of core revenue from online marketing services from its search engine in 2023. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
After a thorough review of the options trading surrounding Baidu, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Baidu</h3>
<ul>
<li>With a volume of 1,940,843, the price of BIDU is down -2.33% at $86.29. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 69 days.</li>
</ul>
<h3>Expert Opinions on Baidu</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $118.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Susquehanna downgraded its action to Neutral with a price target of $85. 
&#x2A; An analyst from Benchmark has decided to maintain their Buy rating on Baidu, which currently sits at a price target of $130. 
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for Baidu, targeting a price of $141. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Baidu with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

BIDU

Behind the Scenes of Baidu's Latest Options Trends

Deep-pocketed investors have adopted a bullish approach towards Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVX usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 23 extraordinary options activities for Chevron. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 43% leaning bullish and 43% bearish. Among these notable options, 13 are puts, totaling $486,061, and 10 are calls, amounting to $1,784,954.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $110.0 to $160.0 for Chevron over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Chevron options trades today is 1716.53 with a total volume of 6,552.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Chevron's big money trades within a strike price range of $110.0 to $160.0 over the last 30 days.
<h3>Chevron Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734633100_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.85</td>
<td>$6.65</td>
<td>$6.83</td>
<td>$160.00</td>
<td>$1.3M</td>
<td>1.1K</td>
<td>2.0K</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$14.45</td>
<td>$14.3</td>
<td>$14.45</td>
<td>$140.00</td>
<td>$72.2K</td>
<td>294</td>
<td>50</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$11.7</td>
<td>$11.6</td>
<td>$11.6</td>
<td>$140.00</td>
<td>$58.0K</td>
<td>501</td>
<td>100</td>
</tr>
<tr>
<td>CVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.55</td>
<td>$4.5</td>
<td>$4.55</td>
<td>$145.00</td>
<td>$57.3K</td>
<td>9.3K</td>
<td>275</td>
</tr>
<tr>
<td>CVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.83</td>
<td>$2.83</td>
<td>$2.83</td>
<td>$145.00</td>
<td>$56.6K</td>
<td>4.0K</td>
<td>455</td>
</tr>
</tbody>
</table>

<h3>About Chevron</h3>
Chevron is an integrated energy company with exploration, production, and refining operations worldwide. It is the second-largest oil company in the United States with production of 3.1 million of barrels of oil equivalent a day, including 7.7 million cubic feet a day of natural gas and 1.8 million of barrels of liquids a day. Production activities take place in North America, South America, Europe, Africa, Asia, and Australia. Its refineries are in the US and Asia for total refining capacity of 1.8 million barrels of oil a day. Proven reserves at year-end 2023 stood at 11.1 billion barrels of oil equivalent, including 6.0 billion barrels of liquids and 30.4 trillion cubic feet of natural gas.
<h3>Present Market Standing of Chevron</h3>
<ul>
<li>Trading volume stands at 6,556,727, with CVX's price down by -1.42%, positioned at $142.03.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 43 days.</li>
</ul>
<h3>What Analysts Are Saying About Chevron</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $180.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Citigroup has upgraded their rating to Buy and adjusted the price target to $185. 
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Chevron, targeting a price of $160. 
&#x2A; An analyst from UBS persists with their Buy rating on Chevron, maintaining a target price of $195. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Chevron, which currently sits at a price target of $173. 
&#x2A; An analyst from Wells Fargo has decided to maintain their Overweight rating on Chevron, which currently sits at a price target of $188. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Chevron, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Chevron: Analyzing the Surge in Options Activity

BITF

BTBT

CIFR

COIN

FUFU

HIVE

IREN

MARA

MSTR

RIOT

WULF

Shares of crypto-related stocks are trading lower amid a drop in Bitcoin.

BSFC

Blue Star Foods To Be Delisted From Nasdaq Following Minimum Bid Price Violation, Trading Suspension Effective December 20, 2024

Stifel analyst Selman Akyol upgraded DT Midstream, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTM#NYSE">DTM</a>) to Buy from Hold and raised the <a target="_blank" href="https://www.benzinga.com/quote/DTM/analyst-ratings" rel="noreferrer noopener">price target to $106 from $89</a>.
The analyst sees the recent stock pullback as an attractive opportunity for investors. With its announced natural gas pipeline acquisition, DTM is positioning itself as a<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42078298/correction-dt-midstream-announces-1-2-billion-acquisition-of-strategic-midwest-ferc-regulated-natu" rel="noreferrer noopener"> leader in natural gas infrastructure</a>.
The acquisition will push DTM&#8217;s EBITDA beyond $1 billion and diversify its customer base, increasing the likelihood of an upgrade to investment grade by S&amp;P, adds the analyst.
The analyst assumes DTM will close the pipeline acquisition at the beginning of 2025, with the assets generating a 10.5x EBITDA multiple, or approximately $115 million.
As a result, Pipeline EBITDA will now account for about 66% of the analyst&#8217;s 2025 EBITDA estimate, up from the previous estimate of 62%.
While Akyol expects year-end 2025 leverage to increase to 3.7x from 3.4x, they view this as manageable given the highly contracted nature of the acquired assets.
Additionally, the analyst anticipates free cash flow after dividends to rise to approximately $240 million, up from $195 million.
Investors can gain exposure to DTM via&nbsp;Invesco S&amp;P Spin-Off ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSD#NYSE">CSD</a>) and&nbsp;Alerian Energy Infrastructure ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENFR#NYSE">ENFR</a>).
Price Action: DTM shares are up 3.31% at $98.53 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42598931" target="_blank" rel="noreferrer noopener">Block Positioned For Margin Expansion And EPS Growth: Goldman Sachs Analyst</a></li>
</ul>

Analyst Color

Upgrades

ENFR

Stifel Sees Opportunity In DT Midstream Pullback: Upgrades Rating On Diversified Growth Potential

Move over, software darlings. The future of tech is being etched in silicon, and chipmakers like NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) are <a href="https://www.benzinga.com/topic/artificial-intelligence">writing the playbook</a>.
Howard Chan, founder and CEO of Kurv Investment Management, shared his exclusive insights with Benzinga, highlighting a sector where he said demand is outstripping supply: "We still favor the hardware or infrastructure side of the AI wave. Chipmakers and cloud computing service providers benefit from existing and future budgeted capital expenditure allocation."
<h1 class="wp-block-heading">Is The Nasdaq-100 Overheating?</h1>
Tech valuations have soared, leaving some investors wondering if growth can keep up. 
"Consensus EPS growth is 21% for Nasdaq-100, up from 15% this year. That might be a tall order, but, after all, they have delivered this for the past&#8230; 20 years,&#8221; Chan said.
Unlike other sectors buckling under high interest rates, tech titans boast robust balance sheets, giving them a cushion. Chan flags the second quarter as pivotal: "The base effect on EPS growth rates will be most obvious in Q2 when the rolling 12-month EPS might bottom."
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42561047/amazon-meta-alphabet-spotify-lead-jpmorgans-2025-tech-picks-for-ai-potential">Amazon, Meta, Alphabet, Spotify Lead JPMorgan&#8217;s 2025 Tech Picks For AI Potential</a>
<h1 class="wp-block-heading">NVDA, AVGO: The Tech Titans To Watch</h1>
Hardware companies such as Nvidia and Broadcom are uniquely positioned to lead the AI boom, according to Chan. "The demand for compute still outstrips the ability of makers to meet that demand. There's small sign of new entrants. However, it will take time for them to catch up."
For investors tracking the sustainability of these gains, Chan offers a roadmap: "For hardware [NVDA/AVGO]: demand from the likes of TSLA/GOOGL/AMZN/META/MSFT."
<h1 class="wp-block-heading">AI: Beyond Tech</h1>
AI's impact isn't confined to tech. Chan sees a ripple effect, particularly in biotech and construction. "Directly, productivity will rise in service industries, although this might take a while as people need to be trained on it." 
Indirectly, AI investments will cascade into non-tech sectors, like construction, as companies expand to meet rising demand, he said. 
As the AI revolution heats up, Nvidia and Broadcom stand as the architects of the next wave, bridging the gap between soaring demand and supply constraints. With EPS growth expectations riding high and demand signals flashing green, the road ahead for tech's chipmakers may be paved in silicon gold.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42569479/openai-takes-a-page-from-googles-2007-playbook-by-turning-phones-into-an-ai-hotline-with-toll-free-number-1-800-chatgpt">OpenAI Takes A Page From Google&#8217;s 2007 Playbook, Turns Phones Into AI Hotlines With 1-800-CHATGPT</a></li>
</ul>
Photo: Shutterstock

Long Ideas

Exclusives

Tech

Interview

AVGO

NVDA

EXCLUSIVE: Nvidia, Broadcom Tipped To Dominate AI Compute Wave By Kurv CEO

Barclays analyst Jared Shaw maintains East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) with a Overweight and raises the price target from $120 to $125.

EWBC

Barclays Maintains Overweight on East West Bancorp, Raises Price Target to $125

Despite a 9% price drop, optimism among XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) traders remains strong, with many holding their positions and <a href="https://www.benzinga.com/money/ripple-xrp-price-prediction">anticipating upward momentum</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>)</td>
<td>&nbsp;$2.26</td>
<td>$129.08 billion</td>
<td>-8.8%&nbsp;</td>
<td>-6.3%&nbsp;</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>&nbsp;$98,630.61</td>
<td>$1.95 trillion</td>
<td>-5.8%&nbsp;</td>
<td>-2.8%&nbsp;</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>)</td>
<td>&nbsp;$3,474.60</td>
<td>$418.8 billion</td>
<td>-10.5%&nbsp;</td>
<td>-11.8%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Crypto trader Javon Marks <a href="https://x.com/JavonTM1/status/1869549362671677783">reflected</a> reflected on XRP's previous bull cycle, during which it achieved a 600x increase.
 He suggests XRP could repeat this performance, potentially climbing 6,800% to around $168 in the current cycle.
Many traders revealed their personal holdings:
<ul>
<li>Doctor Profit <a href="https://x.com/DrProfitCrypto/status/1869693291941511268">pointed</a> out that XRP was overbought on smaller timeframes, signaling an imminent correction. Since his short entry, XRP has dropped 17%, prompting him to secure profits on half his position while holding his long-term spot holdings.</li>
<li>CrediBULL Crypto took a long position after XRP reached an optimal trade entry zone on lower timeframes, <a href="https://x.com/CredibleCrypto/status/1869569451626229945">expressing</a> hope for a rebound.</li>
<li>Blockchainedbb <a href="https://x.com/blockchainedbb/status/1869757817340743867">exited</a> XRP after achieving a 300% gain from his entry price. He plans to re-enter at $1.5–$1.7, maintaining a final target of $7.</li>
</ul>
Statistics: Crypto analyst Ali Martinez <a href="https://x.com/ali_charts/status/1869773183836139733">reported</a> that whales purchased an additional 110 million XRP in the past 24 hours.
Community News: In a Dec. 19 <a href="https://www.youtube.com/watch?v=YFGGA1NZ5Sk">interview</a> with eToro, Ripple CEO Brad Garlinghouse discussed the company's use of stablecoins like USDC and Tether, highlighting that Ripple once minted 20% of all USDC.
Garlinghouse emphasized that stablecoin regulation could position Ripple's RLUSD stablecoin as a key driver for XRP's next rally.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/12/42531943/xrp-price-soars-12-to-268-what-is-going-on">XRP Price Soars 12% To $2.68: What Is Going On With Ripple?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$ETH

$XRP

XRP Price Down 9%% But Ripple CEO Brad Garlinghouse Eyes RLUSD To Fuel Future Rally

OKLO

Oklo shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating on the stock and announced a $25 price target.

In the current market session, Merit Medical Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>) share price is at $97.14, after a 0.01% increase. Moreover, over the past month, the stock decreased by 7.52%, but in the past year, went up by 28.50%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is performing up to par in the current session. 

<img src="https://www.benzinga.com/files/images/story/2024/1734632112_0.png" alt="Past Year Chart" />

<h3>Comparing Merit Medical Systems P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 44.09 in the Health Care Equipment &amp; Supplies industry, Merit Medical Systems Inc. has a higher P/E ratio of 47.38. Shareholders might be inclined to think that Merit Medical Systems Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734632112_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

MMSI

Price Over Earnings Overview: Merit Medical Systems

Wordware, a full-stack operating system for <a href="https://www.benzinga.com/24/12/42310501/playstation-bosses-speaks-about-the-future-of-ai-in-gaming-why-human-creativity-will-always-be-essential-in-game-development">AI development</a>, has secured a $30 million seed round in just seven days. According to Forbes, the round was led by Spark Capital and included participation from Felicis, Y Combinator, Day One Ventures and renowned angel investors such as Paul Graham, Vlad Magdalin (Webflow), Mathilde Collin (Front) and Paul Daugherty (Accenture).&nbsp;
This milestone represents one of the largest seed rounds in <a href="https://www.benzinga.com/news/24/09/40673093/y-combinators-paul-graham-recalls-when-airbnb-ceo-brian-chesky-found-success-by-imitating-this-steve">Y Combinator</a>'s history and signals strong confidence in Wordware's mission to make AI development more accessible to businesses globally.&nbsp;
Don't Miss:
<ul>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
<li>Deloitte's fastest-growing software company partnered with Amazon, Walmart &amp; Target announces the deadline to invest this year is 12/20. – <a href="https://www.benzinga.com/money/mode-mobile-2">Last Chance to get 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
<h2 class="wp-block-heading">Empowering AI Innovation Through Natural Language</h2>
Wordware seeks to transform AI development by introducing plain English as the new programming language for building AI agents. This will allow better collaboration between domain experts and engineers, drastically reducing the time required to create AI solutions.
"Excel gave us power over numbers. Notion gave us power over information. Wordware gives us power over AI. We're creating the new standard for encoding human expertise into AI systems," Filip Kozera, cofounder and CEO of Wordware, told Forbes.
Wordware offers a unified development platform that allows businesses to build sophisticated AI workflows without extensive coding knowledge. Using this model, startups and established enterprises leverage Wordware to streamline operations and deploy AI-driven solutions.
See Also: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">The Founders and Their Vision</h2>
Filip Kozera and Robert Chandler founded the company. The two met while studying deep learning at the University of Cambridge, according to Wordware's website. Their shared passion for artificial intelligence laid the foundation for their partnership. Before founding Wordware, Kozera launched a company focused on augmenting human memory while Chandler led machine learning operations for Five AI, a self-driving technology company later acquired by Bosch.
Their vision became clear as large language models (LLMs) like GPT-3 and GPT-4 began to showcase unprecedented reasoning capabilities. This inspired Kozera and Chandler to reimagine how AI solutions are built.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Rapid Growth and Record-Breaking Success</h2>
The company's journey through Y Combinator showcased the team's ingenuity and market potential. Even before Demo Day, the company had secured multiple term sheets, reflecting investor enthusiasm. By the time the seed round closed, Wordware had raised 15 times the average Y Combinator seed size, according to Forbes.
A highly successful Product Hunt launch fueled this rapid growth. Within weeks, Wordware's early AI application garnered 350,000 users and increased revenue 20-fold.
Nabeel Hyatt, General Partner at Spark Capital, praised the platform's ability to simplify AI development while supporting complex workflows. "Simple is hard to do right. And we were just so impressed by how the Wordware team made AI application development as simple to understand as a Notion document," he told Forbes.
Trending: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today.</a>
<h2 class="wp-block-heading">Unlocking Workplace Potential</h2>
Wordware addresses <a href="https://www.benzinga.com/personal-finance/24/11/42250885/gen-zers-are-being-fired-just-months-after-getting-hired-employers-cite-lack-of-motivation-poor-communication-and-unprofessional-behavior">workplace inefficiencies</a> by empowering employees to automate mundane tasks and focus on creative and strategic thinking. According to PwC, a leading professional services network, 90% of workers are stuck in repetitive tasks, which Gallup says costs the global economy $8.9 trillion annually.
"Today's workplace isn't just inefficient – it's actively suppressing human potential," Kozera explains. By democratizing AI development, Kozera says that Wordware is unlocking a new workplace productivity and innovation era.
<h2 class="wp-block-heading">A Platform for the Future</h2>
With a record-breaking seed round secured, Wordware is poised to revolutionize how businesses and individuals build and deploy AI solutions. The platform's expansion in 2025 will allow more users to harness its capabilities, making AI tools as accessible as any modern software platform.
As AI continues to shape industries worldwide, Wordware sets a new standard, ensuring that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42488785/mks-instruments-is-gaining-traction-in-advanced-technologies-analyst-says">advanced technology</a> remains within reach for innovators at every level.
Read Next:
<ul>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones.  <a href="https://www.benzinga.com/money/mode-mobile-2">The deadline to invest and receive your shares this year is 12/20. Join 30,000+ shareholders and invest at $0.26/share today.</a></li>
</ul>

Startups

Revolutionizing AI: First Full-Stack OS For Development Announces $30 Million Seed Backed By Top Investors

Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade)

Intellia Therapeutics (NTLA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 16. Analyst Mani ...

Intellia Therapeutics' NTLA-2001 Shows Promising Potential with Positive Phase 1 Data and Accelerated Phase 3 Enrollment

Analyst Whitney Ijem of Canaccord Genuity maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target of ...

Positive Buy Rating for Intellia Therapeutics Amid Promising Trial Results for Nex-z in ATTR-CM

20:12 EST Cathie Wood's ARK Investment buys 223.5K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for...

Cathie Wood's ARK Investment buys 223.5K shares of Intellia Therapeutics today

Pfizer meets amyloidosis rival as BridgeBio wins FDA nod for Attruby

Intellia Therapeutics (NTLA) announced that the U.S. Food and Drug Administration, FDA, has granted Regenerative Medicine Advanced Therapy, RMAT, d...

Intellia announces FDA granted RMAT designation to nexiguran ziclumeran

JonesTrading analyst Debanjana Chatterjee has maintained their bullish stance on NTLA stock, giving a Buy rating on November 18. Debanjana Chatterj...

Promising Outlook for Intellia Therapeutics' Nex-z in ATTR-CM Treatment Backed by Safety and Patient Interest

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Lilly tops Morgan Stanley's biopharma pick list for 2025

20:04 EST Cathie Wood's ARK Investment buys 96.2K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for ...

Cathie Wood's ARK Investment buys 96.2K shares of Intellia Therapeutics today

ABBV

ALMS

ALNY

BAYRY

BAYZF

BBIO

BHVN

CABA

GPCR

IONS

NTLA

ONCT

RCUS

REGN

RPRX

SAVA

SRRK

Press Releases

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Earnings

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Comments

Intellia Therapeutics

Interés en corto

Intellia Therapeutics (NASDAQ:NTLA) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL